Visualizing Aβ deposits in live young AD model mice with a simple red/near-infrared-fluorescent AIEgen

Precise and early detection of β -amyloid (A β ) deposits in situ and in real time is pivotal to the diagnosis and early intervention of Alzheimer’s disease (AD). Optical imaging stands out to be a promising technique for such a task; however, it still remains a big challenge, due to the lack of high-performance imaging contrast agent. Restricted by poor blood-brain barrier (BBB) penetrability, short-wavelength excitation and emission, as well as the aggregation-caused quenching effect, the widely used gold-standard probes cannot be used for early in-vivo imaging of A β deposits. Herein, we integrate the A β deposits-favored geometry, amphiphilic and zwitterionic molecular structure, extended D-π-A electronic structure, and 3D conformation into one molecule, facilely establishing a simple and economic imaging contrast agent that enjoys high specificity and affinity to A β deposits, good BBB penetrability, bright red/near-infrared fluorescence, low interference from autofluorescence, aggregation-induced emission (AIE) feature, high signal-to-noise ratio (SNR), and high contrast. In-vitro, ex-vivo , and in-vivo experiments with different strains of mice indicate that AIE-CNPy-AD holds the universality to A β deposits identification. Noteworthily, AIE-CNPy-AD is even able to precisely trace the small and sparsely-distributed A β deposits in AD model mice as young as 4-month-old APP/PS1 mice, the youngest having A β deposits. Moreover, the present probe could clearly reveal the increase and enlargement of A β deposits as the mice grow. Therefore, AIE-CNPy-AD might be an ideal alternative for early AD diagnosis and highly reliable monitoring of AD progression.